BR

BrightPath Biotherapeutics Co., Ltd.

Developing novel cancer immunotherapies, including peptide vaccines and iPS-NKT cell therapies.

4594 | T

Overview

Corporate Details

ISIN(s):
JP3274140007
LEI:
Country:
Japan
Address:
川崎市川崎区殿町三丁目25番22号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

BrightPath Biotherapeutics is a clinical-stage biopharmaceutical company specializing in the development of novel cancer immunotherapies. The company's pipeline encompasses multiple platforms, including cancer peptide vaccines, immuno-modulators, and advanced cell therapies. A primary focus is its proprietary iPS-NKT platform, a novel allogeneic cell therapy that uses natural killer T-cells (NKT cells) derived from induced pluripotent stem cells (iPSCs) for cancer treatment. This technology enables the large-scale, homogeneous production of NKT cells, which are naturally rare. The company, formerly known as GreenPeptide, also develops peptide vaccines like GRN-1201, which has progressed to clinical trials. Its business model covers drug discovery, research, and early-phase clinical development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 07:30
Registration Form
有価証券届出書(組込方式)
Japanese 241.2 KB
2025-11-14 07:34
Registration Form
確認書
Japanese 8.9 KB
2025-11-14 07:34
Interim Report
半期報告書-第23期(2025/04/01-2026/03/31)
Japanese 198.0 KB
2025-06-20 09:01
Post-Annual General Meeting Information
臨時報告書
Japanese 22.8 KB
2025-06-19 08:36
Registration Form
確認書
Japanese 8.9 KB
2025-06-19 08:32
Governance Information
内部統制報告書-第22期(2024/04/01-2025/03/31)
Japanese 23.4 KB
2025-06-19 08:25
Registration Form
有価証券報告書-第22期(2024/04/01-2025/03/31)
Japanese 933.5 KB
2024-11-08 07:35
Interim Report
確認書
Japanese 9.0 KB
2024-11-08 07:34
Interim Report
半期報告書-第22期(2024/04/01-2025/03/31)
Japanese 224.9 KB
2024-06-21 09:07
Registration Form
訂正有価証券届出書(組込方式)
Japanese 254.0 KB
2024-06-21 08:34
Regulatory News Service
内部統制報告書-第21期(2023/04/01-2024/03/31)
Japanese 23.2 KB
2024-06-21 08:33
Registration Form
確認書
Japanese 9.0 KB
2024-06-21 08:32
Annual Report
有価証券報告書-第21期(2023/04/01-2024/03/31)
Japanese 990.5 KB
2024-06-19 08:00
Registration Form
有価証券届出書(組込方式)
Japanese 513.9 KB
2024-02-09 07:12
Report Publication Announcement
確認書
Japanese 9.1 KB

Automate Your Workflow. Get a real-time feed of all BrightPath Biotherapeutics Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BrightPath Biotherapeutics Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BrightPath Biotherapeutics Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.